Edition:
United States

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

89.07USD
16 Jul 2018
Change (% chg)

$-0.64 (-0.71%)
Prev Close
$89.71
Open
$89.62
Day's High
$89.83
Day's Low
$88.84
Volume
709,987
Avg. Vol
1,106,415
52-wk High
$89.87
52-wk Low
$73.70

Chart for

About

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.... (more)

Overall

Beta: 0.20
Market Cap(Mil.): $97,373.96
Shares Outstanding(Mil.): 1,085.43
Dividend: 0.56
Yield (%): 2.53

Financials

  LLY.N Industry Sector
P/E (TTM): 30.86 29.26 33.20
EPS (TTM): 2.89 -- --
ROI: 10.15 13.66 13.23
ROE: 21.28 15.51 15.28

Novo reveals more Ozempic data on change in body weight by baseline BMI

COPENHAGEN, June 23 Diabetes drugmaker Novo Nordisk presented a post-hoc analysis of the SUSTAIN 7 trial comparing treatment effect in body weight across baseline BMI subgroups receiving Novo's Ozempic or Eli Lilly's dulaglutide, marketed as Trulicity.

Jun 23 2018

UPDATE 2-Lilly gets U.S. nod for arthritis drug, sets price well below rivals

* Drug priced at $25,000/year, 60 pct lower to AbbVie's Humira

Jun 01 2018

Novo Nordisk's oral diabetes drug beats Jardiance in study

LONDON, May 29 An experimental diabetes pill from Novo Nordisk proved better at lowering blood sugar levels than Eli Lilly and Boehringer Ingelheim's established Jardiance in a clinical study, the Danish drugmaker said on Tuesday.

May 29 2018

REFILE-UPDATE 5-Zoetis to buy veterinary diagnostics firm Abaxis for $1.9 bln

* Zoetis says diagnostics should grow faster than animal health

May 16 2018

Lilly to buy cancer drug developer AurKa Pharma

Eli Lilly and Co will buy AurKa Pharma Inc in a deal potentially worth up to $575 million, the U.S. drugmaker said on Monday, seeking access to the privately-held firm's experimental cancer treatment for solid tumors.

May 14 2018

Eli Lilly to buy cancer drug developer AurKa Pharma

May 14 Drugmaker Eli Lilly and Co said on Monday it would buy AurKa Pharma Inc to get access to the privately-held company's experimental cancer treatment for solid tumors.

May 14 2018

BRIEF-HBM Healthcare Investments: Eli Lilly Announces Tender Offer For HBM-Portfolio Company

* ELI LILLY ANNOUNCES TENDER OFFER FOR HBM-PORTFOLIO COMPANY ARMO BIOSCIENCES FOR USD 1.6 BILLION

May 11 2018

BRIEF-Armo Biosciences - Upon Termination Of Merger Under Specified Circumstances Co May Be Required To Pay Eli Lilly Fee Of $63.4 Mln

* ARMO BIOSCIENCES - UPON TERMINATION OF MERGER UNDER SPECIFIED CIRCUMSTANCES CO MAY BE REQUIRED TO PAY ELI LILLY TERMINATION FEE OF $63.4 MILLION Source: (https://bit.ly/2I7j4vd) Further company coverage:

May 10 2018

Lilly to buy Armo Biosciences for $1.6 billion to bolster cancer pipeline

Eli Lilly and Co said on Thursday it would buy Armo BioSciences Inc for about $1.6 billion to expand its portfolio of drugs that helps body's immune system fight cancer as the U.S. drugmaker chases rivals in a lucrative market.

May 10 2018

Lilly to buy Armo Biosciences for $1.6 bln

May 10 Drugmaker Eli Lilly and Co said on Thursday it would buy Armo BioSciences Inc for about $1.6 billion to get access to the drug developer's experimental cancer treatment.

May 10 2018

Competitors

Earnings vs. Estimates